Graminex社の”花粉エキスG63”による前立腺炎への知見

食事編_表1_4_0508

取扱説明書

ED-601 ED-501 ED-401 2 3 4 23 14 5 6 18 10 7 1 2 6 3 4 8 9 16 16 16 12 1 2 18 10 2 1 5 12 11 1 2 1 2 12 1 2 13 16 14 3 2 4 1 1 2 16 3 4 18 15 1 2 16 2 3 1 1 2 3 18 17 18 22 19 D A C 20 A B 22 B C D 22

グラミネックス社の花粉エキス

, Pollen Aid TM Graminex L.L.C. 95 Midland Road, Saginaw, MI 48603 U.S.A. www.graminex. com 2000 1 40 4 300 3 ISO 9001, Q9001-2000, ng.m.p. 1 G60 GFX( ) 20:1 G63 1980 22 27 100 G60 GFX G63(G60 GFX ) 2

02

Q A Ax Pb Ni Cd Hg Al Q A Q A Q A 1 2 3 2 0 1 2 3 4 5 6 7 0 1 2 3 4 5 6 7 8 0 0 1 2 3 4 1 0 1 2 Q A ng/ml 4500 D H E A 4000 3500 3000 2500 2000 DHEA-S - S 1500 1000 500 0 10 15 20 25 30 35 40 45

14 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 20 0 0 0 0 0 0 0 0 0 0 0 0 21 0 0 0 0 0 0 0 0 0 0 0 0 22 0 0 0 0 0 0 0 0 0 0 0 0 23 0 0 0 0 0 0 0 0 0 0 0 0 24 0 0 0 0 0 0 0 0 0 0 0 0 25 0 0 0 0 0 0 0 0 0

第３章 焼却灰溶融システムの現状、焼却灰溶融スラグのリサイクルの動向・問題点

18 5 23 450 100~150 1300 1998 10 25 1 1 27 1819 60 3 300t 28.8t 2 62 118t16 12.3 16h 24 3 4 120t 9.6t24h 3 4 100t24h 15t24h 3 4 600t24h 500t24h 5 2 300t24h 75t24h 6 8 80 24h 9.6 24h 4 300t24h 52 24 11

152273335 1 123 11531 2 5 24 31 2 154301482 1551 JAS 100 2000 105 1101 1 2JAS 1-2 1

152273335 1 123 11531 2 5 24 31 2 154301482 1551 JAS 100 2000 105 1101 1 2JAS 1-2 1 JAS 1-2 1-2 112 13 1-11-13 100870mg 100830mg11000 1100020.002 2 50 100 2 100 500 2 100 109252165 4514782 7 2.0kg 2-19220.05kg0.2kg

.H...A.....M.[00.\...\01.^.O.Z

EL-G37

EL-G37 A A A A A A A A A A A A A A GT F543210A CE CA 4 00. 00 23.80 2 015.6250 77.14286 96. 91. 102. 25. 9. 1 700. 2 720. 2.5 7. 20. 25. 220. 400. 4 096. 4.685 0.084 M 125. M 28. M 85.

12-7 12-7 12-7 12-7 12-8 12-10 12-10 12-10 12-11 12-12 12-12 12-14 12-15 12-17 12-18 10 12-19 12-20 12-20 12-21 12-22 12-22 12-23 12-25 12-26 12-26 12-29 12-30 12-30 12-31 12-33 12-34 12-3 12-35 12-36

untitled

~ ~ ~ ~ ~ 22 14 10 50cm 2124 15 21 29.5 11, 12 12 20 4040 10 60 60 10 20 20 11 ç ç çç 6070 ç ç çç p. ç çç 4.5cm2.5cm 25 http://www.crdc.gifu-u.ac.jp/edsoftol/water/

橡アロマセラピー症状別処方例.PDF

1 1 92 E 100ml 1 2 2 1 93 0.5m 10ml 100ml 1 2 3 2 52 0. l 2 4 3 27 3 1 1 3 3 4 5 3 2g 2 3 1 1 1 10ml 3 4 6 3 29 2 2 2 10ml 3 3 4 7 3 30 2 1 2 10ml 3 3 4 8 3 31 1 1 1 1 3 60 10 10 3 2 4 10ml A 2 3 61 20

1 2 3 4 5 68g 9g 2g 0.2mg 0.8mg 316kcal 316cal 326kcal 326cal 6 010 3035 15 5355 30 120 20 7 8 9 10 11 () () () 12 1 3 1 5 1 80kcal 20 30 20 30 1 9 7.5 13 7.58.5 910.5 1213.5 11.512.5 14 15 79 23 1520

001-007　扉・口絵・目次

1 6 6 7 1 a a a a 2 a a a 3 4 5 a 6 7 8 9 10 a 11 a a a 12 13 14 15 a 16 17 18 19 20 21 22 23 24 b b 25 b 26 27 aa 28 r r 29 a s d f 30 b b 31 32 33 1 34 35 36 37 38 6 39 6 40 41 42 43 44 45 7 47 48

w

22

2015 75 7074 6569 2064 26470 21 22 4,060 1,330 23 24 15,000 80 24,600 15,000 15,000 24,600 15,000 24,600 15,000 24,600 37,200 145 520 383 44,400 25 26 280 160280 280 346 160 80 160 37,200 24,600 15,000

partial androgen deficiency in agingmalepadam lateonset hypogonadism LOH ED 3 Aging Males Symptoms scale AMS androgen androgen androgen androgen Morley JE 17 52.3 20 48.5 STAI SDS STAI TEG N A C 40 2 2

2011 2011 2011 100/m 0.003/ 0.0005 / 0.01/ 0.01 / 0.01/ 0.05 / 0 0.0003 0.00005 0.001 0.001 0.001 0.005 0 0.0003 0.00005 0.001 0.001 0.001 0.005 0 0.0003 0.00005 0.001 0.001 0.001 0.005 0 0.0003 0.00005

サプリメント4.PDF

Vol.13,No,2004 106 Oct.200Vol.13 No. ACE 1000 10mmHg ACE ACE ACE Vol.13,No.4,2004 107 L- L- EPA DHA B 2002 a. CSPHP A D E K b. TG DAG DA EPA/DHA EPA DHA n-3 n- EPA DHA n- EPA DHA Vol.13,No,2004 108 n-6

untitled

28 20 1 31 4 2 25 1 IgG IgA IgM IgE IgM 2 60 80 70 60 60 40 20 80 35 45 kg 150cc 100 120cc 100cc 30 40cc 7,000g 500cc 120cc 120 5=600cc 600g 30 2,100cc 1,000cc 3 4 14 5 6 7 8 9 10 11 12 SIDS SIDS SIDS

FXneo FXneo PC FXneo FX 1 2

FXneo FXneo PC FXneo FX 1 2 FXneo 1. 04 2. 07 PC FX 07 08 09 10 11 13 3. 14 14 19 4. 20 5. 21 3 FXneo 1. 1 4 FXneo 1. 1 1 / 1 5 FXneo 1. 1 2 6 FXneo 2. PC PC FXneo- 2 [ ] 7 FXneo 2. PC 8 FXneo 2. PC 50pips

馬のライフステージ別栄養管理　Ⅰ　～繁殖牝馬～

untitled

...1... 3 1... 3 2... 4 3... 4 4... 5...... 6 1... 6 2... 7 3... 8 4... 9 5... 10... 12 1... 12 2... 13 3... 14 4... 16...... 19 1... 19 2... 20 3... 22 4... 24...... 25... 26 1... 26 2... 26 3... 26......

‚å™J‚å−w“LŁñfi~P01†`08

156 2003 2 3 4 5 6 7 8 9 c f c a g 10 d c d 11 e a d 12 a g e 13 d fg f 14 g e 15 16 17 18 19 20 21 db de de fg fg g gf b eb g a a e e cf b db 22 d b e ag dc dc ed gf cb f f e b d ef 23 f fb ed e g gf

近畿中国四国農業研究センター研究報告　第７号

230 C B A D E 50m 558 0 1km (mg L 1 ) T N NO 2 3 N NH 4 N 2.0 0 (a) 2001 1.5 6 20 21 5 1.0 0.5 0.0 2.0 1.5 1.0 0.5 0.0 14:00 17:00 (b) 2001 7 3 4 20:00 23:00 2:00 (h) 5:00 8:00 11:00 10 0 5 10 15

, ,279 w

No.482 DEC. 200315 14 1754,406 100.0 2160,279 w 100 90 80 70 60 50 40 30 20 10 28.9 23.8 25.0 19.3 30.4 25.0 29.5 80.7 75.0 75.0 70.5 71.1 69.6 76.2 7 8 9 10 11 12 13 23.2 76.8 14 14 1751,189 100.0 2156,574

国試過去問集.PDF

I 89 16 3 130 ab c AMPcAMP a 1 --- b c --- 2 --- --- 3 --- --- 4 --- --- 5 --- --- camp camp Ca 2+ β1 camp A camp camp A β1 p.156 β p.146 b. p.157 p135 (ANP) p157 c PDE-III p.157 p.157, 183 PDE C Ca PDE-III

200 30 984 1 1854 1713 1000 1008 ED ADL/QOL The European Working Group on Sarcopenia in Older People EWGSOP Asian Working Group for Sarcopenia AWGS D C Zhang, 2006 C Imamura, 2008 ATP Imamura, 2009 Imamura,

NG 3 1 MDI 製 剤,DPI 製 剤 違 い MDI DPI 表 1MDIDPI 表 2 58

1 第 1 NG 2 57 NG 3 1 MDI 製 剤,DPI 製 剤 違 い MDI DPI 表 1MDIDPI 表 2 58 2 使 用 可 能 な 吸 入 ステロイドと 投 与 量 目 安 MDI DPI g g g 100200 400 800 第 DPI 100200 400 800 DPI 200400 0.5mg 800 1.0mg 1600 2.0mg 100200 400 800

2014 6 115 123 総 説 I -VG, 2014 7 24 2014 8 15 -VG, -VG 115

2014 6 107 114 総 説 2014 7 25 2014 8 1 2014 1 20 OTC 107 2014 6 115 123 総 説 I -VG, 2014 7 24 2014 8 15 -VG, -VG 115 2014 6 124 132 原 著 1, 2, 3 4, 5 6 7 8 9 10 3 11 12 1 2 3 4 5 6 7 8 9 10 11 12 2014 3 24

1 8 7 30 8 15 12 11 30 12 15 18 18 00 18 30 10 15 19 30 9 45 13 45 11 30 18 9 15 30 30 1 1 2

7 19 20 30 1 1 8 7 30 8 15 12 11 30 12 15 18 18 00 18 30 10 15 19 30 9 45 13 45 11 30 18 9 15 30 30 1 1 2 3 10 11 12 13 4 6 6 14 15 16 17 18 5 1 1 6 2 7 () 8 9 10 - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - -

1 X X T T X (topology) T X (open set) (X, T ) (topological space) ( ) T1 T, X T T2 T T T3 T T ( ) ( ) T1 X T2 T3 1 X T = {, X} X (X, T ) indiscrete sp

1 X X T T X (topology) T X (open set) (X, T ) (topological space) ( ) T1 T, X T T2 T T T3 T T ( ) ( ) T1 X T2 T3 1 X T = {, X} X (X, T ) indiscrete space T1 T2 =, X = X, X X = X T3 =, X =, X X = X 2 X

untitled

2 prologue Magnesia Alba 3 #01 about Magnesium 4 #01 about Magnesium 6 7 #02 in the Athletes Life 8 9 #02 in the Athletes Life 10 11 #02 in the Athletes Life 12 13 Athlete's Life Magnesium #03 Q A 14

untitled

prologue Magnesia Alba 2 3 4 about Magnesium #01 #01 about Magnesium 6 7 #02 in the Athletes Life 8 9 #02 in the Athletes Life 10 11 12 13 in the Athletes Life #02 14 15 #03 Athlete's Life Magnesium Q

231 331 812 230 350 500 100 30 50 100 150 580291954 500100 50175 500 15700 80 200 391964 224 1990 521977 1997 232 51 391964 225 25 26 27 28 29 30 233 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 234 46

Y z x c n m, 0 3 4 5

Y z x c n m, 0 3 4 5 5 K K K 5 7 65 65 Y Y o o 56 65 7 s s s s s @ x v z c \ b z x c \ c e 0 d b f d 65 C C D E F B E k 7 k 778 23 k 850 778 0 C C F F C 5 F F ^ C B E B F F O O P 5 5 Z D D D D B F C F

1) 1) 1 R 2 3 4 5 6 3) 4) 5) Punch 7 10g/mL(63.6mol/L) 20mg/kg 78 5 23 Cmax 250mg 3.9g/ml 500mg 6.0g/ml1000mg 8g/ml2000mg 15g/ml 33.4 110-116mL/min 1,8) 8 95 9 10 ( ) 11 desa 12 13 12) 2.5 5 19 Rec assayames

1総説_諸疾患における亜鉛測定の意義.indd

O 43,000 C 16,000 H 7,000 N 1,700 Ca 1,160 P 670 K 150 S 112 Cl 85 Na 63 Mg 25 70 100 3 5mg 15 mg 0.5 0.1 mg 0.1 3.0 mg 0.5 1.0 mg 1.0 5.0 mg -P B 12 0.01 0.06 mg 0.02 0.2 mg 0.01 0.04 mg 0.02 0.2 mg 0.1

1 1 ー (LPG ) (LPG ) LNG ( ( ) () LPG LNG LPG LNG 2 10^6 kwh () TJ () TJ () TJ (LPG) TJ TJ m 3 1990(H2)2005 1990 LPG L/

62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC -

1 62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC - 62 [ ] [ ] [ ] g/dl A 62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC - 62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC - [ ] Point ~ 62 [ ] [ ] [ ] [ ] [ ] [ ] / /

function2.pdf

2... 1 2009, http://c-faculty.chuo-u.ac.jp/ nishioka/ 2 11 38 : 5) i) [], : 84 85 86 87 88 89 1000 ) 13 22 33 56 92 147 140 120 100 80 60 40 20 1 2 3 4 5 7.1 7 7.1 1. *1 e = 2.7182 ) fx) e x, x R : 7.1)

% %

4 8 4 5 414.5 172.1 41.5% 39.8 10% 17 186.4 70.8 4 9 10 11 3 1-1 - 2-2 - - 3 - 10% - 4 - 4060% 5560% 60% 40% 3040 1520 1015 411 7 4 11 610 7080 5060 100 3040 13-5 - 1015 4045 3.04.0 5.06.0 1.52.0 1.01.5

< B C8B816982C682D182E7816B90468E86816C8ADC82DE816A2E696E6464>

L LM L B 12 c c L G L G L G L G L G L G bcb c L K J a B C 19 0de G c A f b b 123 G G 1 f 5 G G G G Gf d 09 d B 3 G f 3 G G G 1 2 1 2 G G G 1 G 1 G 2 3 1 2 G G G 1 G B B 1 2 3 4 5 6 7 8 9 G 2 2 B 12 f 4

簡易入力システム（よくある質問集）

1 1. 4 2. 5 3. 6 3.1.... 6 3.2.... 8 3.3.... 10 3.4.... 12 4. 13 5. 20 6. 21 7. 22 23 1.... 24 2.... 38 3.... 39 4.... 58 5.... 59 61 1.... 61 1.1.... 61... 61... 63... 64 2... 65 2... 66 2... 67... 68...

IF MR 63 IF 10 IF IF IF IF A4 IF IF IF 11 IF IF IF IF MR IF IF MR Drug Safety Update() IF

200823 877122 IF19989 HYDROPHILIC OINTMENT 1g 250mg 200mg 120mg 60 40mg 10mg 1mg 1mg HydrophilicOintment 200821 19518 19977 IF20082 IF MR 63 IF 10 IF IF IF IF A4 IF IF IF 11 IF IF IF IF MR IF IF MR Drug

,

23 1948 23 10 20 23 11 6 10 10 214 11 11 4 6,000 6,000 215 24 1949 18 69 1 2 24 31 34 24 10 11 12 14 15 2 2226 83, 24 1949 25 195017 26 1951 10 12 28 1953 22 25 1 20 31 10 15 10 1631 10 11 12 13 14 13

( ), ( ),,,,,

( ) ( ), ( ),,,,, ( ). ( ), ( ) ( ) ( ) ( ).. %. %.. %... %.. % ( ) ( ) , ( ) ( ). ( )...,.,.....,. ( ) ( ) ( ) ( ) ( ) B A / C ( ) ( ) ( ) ( ) B A,,,, ( ) ( )......... kg. kg =. kg. =. kg kg... kg....